

And Human Immunodeficiency Virus (HIV)," 57 *J. Org. Chem.*, pp. 2217-2219 (1992).

Belleau et al., "Design And Activity Of A Novel Class Of Nucleoside Analogs Effective Against HIV-1," Fifth International Conference On AIDS, Montreal, Canada, Abstract T.C.O.1 (1989).

Carlisle et al., "Cellular Pharmacology Of The Anti-HIV Agent BCH-189 (2'-Deoxy-3'-Thiacytidine) In Human Peripheral Blood Mononuclear Cells (PBMC)", *American Association For Cancer Research Proceedings*, 31 Abstract 2435 (1990).

Chang et al., "Deoxycytidine Deaminase-resistant Stereoisomer Is the Active Form of (\pm)-2',-3'-Dideoxy-3'-thiacytidine in the Inhibition of the Hepatitis B Virus Replication," 267 *J. Biol. Chem.*, pp. 3938-3942 (1992).

Coates et al., "The Separated Enantiomers of 2'-Deoxy-3'-Thiacytidine (BCH 189) Both Inhibit Human Immunodeficiency Virus Replication in Vitro," 36 *Antimicrobial Agents & Chemotherapy*, No. 1, pp. 202-205 (1992).

Doong et al., "Inhibition of the Replication of Hepatitis B Virus In-Vitro By 2'3' Dideoxy-3'-thiacytidine and Related Analogues," *Thirty-first Annual Interscience Conference of Antimicrobial Agents and Chemotherapy*, Chicago, IL, USA, 29 Sep.-2 Oct. 1991, *Program Abstract* 31(0) 181 (1991).

Doong et al., "Inhibition of the Replication of Hepatitis B Virus in vitro by 2',3'-dideoxy-3'-thiacytidine and related analogues," 88 *Proc. Natl. Acad. Sci., USA*, pp. 8495-8499; 88 *Physiology/Pharmacology* 8495-8499 (1991).

Greenberg et al., "Metabolism, Toxicity, and Anti-HIV Activity of 2'-Deoxy-3'-Thia-Cytidine (BCH-189) in T and B Cell Lines," 616 *Annals of the New York Academy Of Sciences* 517-518 (1990).

Kassianides et al., Abstract: "Effects of 2',3'-dideoxycytidine on Duck Hepatitis B Virus," 94 *Gastroenterology* No. 5, A552 (1988).

Kassianides et al., "Inhibition of Duck Hepatitis B Virus Replication by 2',3'-Dideoxycytidine," 97 *Gastroenterology*, No. 5, 1275-1280 (1989).

(List continued on next page.)


Primary Examiner—Jerome D. Goldberg

Attorney, Agent, or Firm—Fish & Neave; Leslie A. McDonell; Gerald J. Flattmann, Jr.

[57]

ABSTRACT

Use of a compound of formula (I) or a pharmaceutically acceptable derivative thereof in the manufacture of a medicament for the treatment of hepatitis B is disclosed.



9 Claims, No Drawings